Posts for Ticker ‘GENZ’

Stocks That Missed the Rally (ABT, MO, AWK, BKC, ENER, GENZ, KR, ORB, WMT, LEAP, PCS)

Here we are going into yet another earnings season.  We saw Monday how the market has rallied significantly from the March lows and the major indexes are even up in positive territory for the 2009 calendar.  The DJIA is up 51% from its absolute lows of March, and the S&P 500 has rallied more than 61% from its absolute lows in March.  If you look at the December 31, 2008 closing bell levels, the DJIA is now up about 12.75% and the S&P 500 is now up more than 19% year-to-date.

But almost as always, there are still some key very large and/or very active stocks which have not recovered anywhere close to the same amounts with the overall stock markets.  Some of these lagging stocks are Abbott Laboratories (NYSE: ABT), Altria Group Inc. (NYSE: MO), American Water Works Company, Inc. (NYSE: AWK), Burger King Holdings Inc. (NYSE: BKC), Energy Conversion Devices, Inc. (NASDAQ: ENER), Genzyme Corp. (NASDAQ: GENZ), Kroger Co. (NYSE: KR), Orbital Sciences Corp. (NYSE: ORB) and Wal-Mart Stores Inc. (NYSE: WMT).  Two similar situation stocks that are Leap Wireless International Inc. (NASDAQ: LEAP) and MetroPCS Communications Inc. (NYSE: PCS).  We wanted to explore the forward values and relative performance, and the consensus estimates based upon Thomson Reuters data.  Only two of these stocks have market capitalization rates under $1 billion, and almost all are very actively traded and well known in their sectors.
Read More »

Posted on: October 12, 2009 – 5:03 pm in Biotech, Charts, Consumer Goods, Defensive Stocks, Dividend, Editor's Picks, Retail, Utilities, Value Investing, Water, , , , , , , , , , ,

Top 10 Analyst Upgrades & Downgrades (ATK, CELG, NTAP, NVLS, WMT, ATHN, ARNA, BK, GENZ, Q)

These are the top 10 analyst upgrades, downgrades, and initiations we have seen early this Monday morning:

Alliant Techsystems (ATK) Started as Buy at Jefferies.
Celgene (CELG) raised to Outperform at R.W.Baird.
NetApp (NTAP) raised to Conviction Buy List at Goldman Sachs
Novellus (NVLS) Raised to Outperform at Credit Suisse.
Wal-Mart (WMT) Started as Overweight at HSBC.
Athenahealth (ATHN) started as Sell at Citigroup.
Arena Pharmaceuticals (ARNA) cut to Market Perform at Leerink Swann.
Bank of New York Mellon (BK) Cut to Neutral at Goldman Sachs.
Genzyme (GENZ) Cut to Perform at Oppenheimer.
Qwest (Q) Cut to Conviction Sell List, but was already a Sell, at Goldman Sachs.

JON C. OGG

Posted on: September 21, 2009 – 8:21 am in Analyst Calls, , , , , , , , , ,

Top Analyst Downgrades (ATHN, SCHW, FPL, GENZ, IMAX, SONC)

These are this Friday’s top analyst downgrades and cautious research calls we have seen from Wall Street firms:

athenahealth (ATHN) Cut to Sell at Auriga.
Charles Schwab (SCHW) Cut to Sell at Goldman Sachs.
FPL Group (FPL) Started as Underweight at Morgan Stanley.
Genzyme (GENZ) Cut to Hold at Deutsche Bank.
IMAX (IMAX) Cut to Buy at Merriman Curhan Ford.
Sonic (SONC) Cut to Underweight at Piper Jaffray.

JON C. OGG

Posted on: September 18, 2009 – 8:07 am in Analyst Calls, , , , , ,

Top Analyst Upgrades and Downgrades (BIIB, FRX, GENZ, GILD, HOLX, LVS, MOS, NVAX, RIG, TXT)

These are the top ten analyst research initiations, upgrades, and downgrades we have seen from top Wall Street firms early this Wednesday morning:

Biogen-Idec (BIIB) Started as Underperform at BofA/Merrill Lynch.
Forest Labs (FRX) Cut to Hold at Needham.
Genzyme (GENZ) Started as Buy at BofA/Merrill Lynch.
Gilead (GILD) Started as Buy at BofA/Merrill Lynch.
Hologic (HOLX) Cut to Hold at Canaccord.
Las Vegas Sands (LVS) Raised to Buy at Argus.
Mosaic (MOS) Started as Sector Perform at CIBC.
Novavax (NVAX) Cut to Market Perform at Rodman & Renshaw.
Transocean (RIG) Started as Outperform at BMO Capital.
Textron (TXT) Raised to Conviction Buy List at Goldman Sachs.

JON C. OGG

Posted on: September 2, 2009 – 8:21 am in Analyst Calls, , , , , , , , , ,

Top Day Trader Alerts (AIG, BJS, BHI, GENZ, FNM, FRE, HGSI, MVL, DIS)

These are Monday’s top day trader and active trader alert stocks.  We have links through to each with more detailed price/volume analysis over at VSinvestor.com:

American International Group (NYSE: AIG) is giving back some of last week’s gains after Barron’s gave a harsh reminder here.

BJ Services Company (NYSE: BJS) is surging on a deal where Baker Hughes Inc. (NYSE: BHI) is acquiring the company….

Genzyme Corporation (NASDAQ: GENZ) is down over 3% on a downgrade and ahead of an FDA review date tomorrow.

Fannie Mae (NYSE: FNM) and Freddie Mac (NYSE: FRE) are both getting their wings clipped after FBR reminds of no underlying value remaining….

Human Genome Sciences, Inc. (NASDAQ: HGSI) is getting clipped as buyout hopes fade.

Marvel Entertainment, Inc. (NYSE: MVL) is surging after being acquired in a serious surprise merger by Walt Disney Co. (NYSE: DIS).

If you wish to be notified by email when the top day trader alerts hit, along with news of IPO’s, key offerings, guru investor data on Buffett and others, mergers, and more, you can join our open email distribution list which goes out several times per week.

JON C. OGG

Posted on: August 31, 2009 – 9:09 am in Pre-Market Activity, Trading Alert, , , , , , , , ,

Top Analyst Downgrades (AGO, CP, KOF, GENZ, SHAW)

These are some of the top early-bird analyst downgrades and cautious research calls we have seen from Wall Street analysts early this Monday morning:

Assured Guaranty (AGO) Cut to Neutral at UBS.
Canadian Pacific Railway (CP) Cut to Neutral at UBS.
Coca-Cola Femsa (KOF) Cut to Sell at UBS.
Genzyme (GENZ) Cut to Neutral at Baird.
Shaw Group (NYSE: SHAW) Cut to Neutral at JPMorgan.

JON C. OGG

Posted on: August 31, 2009 – 8:02 am in Analyst Calls, , , , ,

When Key Biotechs Have Low P/E’s & Value Screens (AMGN, BIIB, CEPH, CBST, GENZ, PDLI)

Biotech ImageIt usually takes an event or a series of events for biotech stocks to ever look cheap compared to the overall market or even to sub-sectors within health care.  They generally trade at higher multiples of revenues and with high P/E ratios, assuming they even have real sales-generated revenues and earnings.  But in today’s climate there are many of the large key biotech stocks that are now trading with market-discounts on the P/E ratios and on multiples of revenues as valuation metrics.  We ran a full screen for BioHealthInvestor.com and some of the key names that came up with low P/E and revenue multiples were Amgen Inc. (NASDAQ: AMGN), Biogen Idec Inc. (NASDAQ: BIIB), Cephalon Inc. (NASDAQ: CEPH), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Genzyme Corporation (NASDAQ: GENZ), and PDL BioPharma, Inc. (NASDAQ: PDLI).

There are generally some reasons that have gotten these to cheap screening levels, but some of these are showing significant value for a sector that usually commands a high-premium to most sectors.  Amgen has recovered substantially from its woes, and Biogen has as well.  Genzyme’s troubles allowed it to make the screen with some key caveats, and the valuation screens elsewhere showed that Cephalon, Cubist, and PDL are worth a look.  All of these companies were also well above our screening threshold of $400 million in market cap and average volume of 250,000 shares or more.  These all came in above $1 billion in market cap and most never see under 1 million shares per day in average volume.

The full story is available at BioHealthInvestor.com.

-The 24/7 Wall Street Team

Posted on: August 24, 2009 – 9:54 am in Biotech, Drug companies, Value Investing, , , , , ,

The Unusual Suspects (MELA, FSLR, GENZ, GERN, JEC, SHLD, SIRI, CRM, SPPI)

bull-and-bear-imageIt’s the weekend, and that brings about the review of “the unusual suspects” for strange activity or for being key stocks under review for the week ahead.  There are some old hat names here and some new unknown names that will be key.  We have Electro-Optical Sciences, Inc. (NASDAQ: MELA), First Solar, Inc. (NASDAQ: FSLR), Genzyme Corp. (NASDAQ: GENZ), Geron Corp. (NASDAQ: GERN), Jacobs Engineering Group, Inc. (NYSE: JEC), Sears Holdings Corporation (NASDAQ: SHLD), SIRIUS XM Radio Inc. (NASDAQ: SIRI), Salesforce.com (NYSE: CRM), and Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) all under review for the week ahead.
Read More »

Posted on: August 22, 2009 – 11:16 am in Calendar, Earnings, Editor's Picks, The Week, Trading Alert, , , , , , , , ,

Genzyme Taking Aim At Resolution (GENZ)

Genzyme Corp. (NASDAQ: GENZ) has taken steps to remedy its situation with the FDA and to remedy its image.  Genzyme issued some new guidance with an investor update and said it would discard the majority of the work-in-process material under question. Genzyme had been hitting 52-week lows last week as a result of its woes.  Shares closed up almost 5% at $50.54 today, and the after-hours session looks up marginally at $50.70 in thin trading.

Read More »

Posted on: August 10, 2009 – 4:59 pm in Biotech,

The Unusual Suspects (MS, GENZ, SPPI, CBST, DNDN, OPXA, BRK-A, FRED, GSIC, AMAT, WMT, LEAP, PCS)

We have some very unusual developments that came late in the week that we want you to keep on your watch lists for the coming week.  We also included the big events coming down the pipe for next week.  Morgan Stanley (NYSE: MS) is of ongoing interest.  Genzyme Corp. (NASDAQ: GENZ), Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Dendreon Corp. (NASDAQ: DNDN), Opexa Therapeutics, Inc. (NASDAQ: OPXA) are all of special interest this next week.  Other key issues to watch will be Berkshire Hathaway Inc. (NYSE: BRK-A), Fred’s Inc. (NASDAQ: FRED), GSI Commerce Inc. (NASDAQ: GSIC), Applied Materials Inc. (NASDAQ: AMAT), Wal-Mart Stores Inc. (NYSE: WMT), Leap Wireless (NASDAQ: LEAP), and MetroPCS (NYSE: PCS).
Read More »

Posted on: August 8, 2009 – 11:47 am in Biotech, Calendar, Earnings, Economy, Rumors, Secondary Offering, Semiconductor, Technology Companies, Wireless, , , , , , , , , , , , ,

Top 10 Analyst Upgrades and Downgrades (AGN, BKC, BEN, GPS, GENZ, HURN, MMM, SSS, WEN, UTHR)

These are the top ten analyst upgrades and downgrades we have seen from Wall Street firms early this Monday morning:

Allergan (AGN) Raised to Outperform at Baird.
Burger King (BKC) Cut to Neutral at JP Morgan.
Franklin Resources (BEN) Raised to Buy at Goldman Sachs.
Gap (GPS) Raised to Overweight at Barclays.
Genzyme (GENZ) Cut to Neutral at UBS.
Huron (HURN) Cut to Hold at Deutsche Bank; Cut to Underperform at Oppenheimer; Cut to Underperform at Baird.
3M (MMM) Raised to Buy at Goldman Sachs.
Sovran Self Storage (SSS) Cut to Underperform at Oppenheimer.
Wendy’s (WEN) Raised to Buy at UBS.
United Therapeutics (UTHR) Cut to Hold at Jefferies.

Jon C. Ogg
August 3, 2009

Posted on: August 3, 2009 – 7:43 am in Analyst Calls, , , , , , , , , ,

The Unusual Suspects (TSN, CSCO, GENZ, ARIA, VHC, XOM, USU, EBAY, FUQI)

It always good to keep watch lists.  There were some key issues over the last week that will have important implications for the coming week (or weeks).  This is definitely the case for Tyson Foods Inc. (NYSE: TSN) and Cisco Systems, Inc. (NASDAQ: CSCO), both on deck for earnings this week.  In biotech land, your two key earnings reports will be in Genzyme Corporation (Nasdaq: GENZ) and Ariad Pharmaceuticals Inc. (Nasdaq: ARIA).  A tiny company called VirnetX Holding Corporation (NYSE Amex: VHC) got itself on the map and will continue to be one to watch.  Exxon Mobil Corp. (NYSE: XOM) and USEC Inc. (NYSE: USU) now both have issues, although for entirely different reasons.  eBay, Inc. (NASDAQ: EBAY) also landed itself on the cover of  Barron’s and Fuqi International, Inc. (NASDAQ: FUQI) scored a different top prize.

We have compiled detailed reviews here for those charts and what to look for in the coming week and beyond.
Read More »

Posted on: August 1, 2009 – 10:29 am in Biotech, Charts, China, Earnings, Editor's Picks, Options, Technology Companies, Trading Alert, , , , , , , , ,

Generic Biotech Drug Approval in Japan, Implications in U.S. and Abroad (NVS, PFE, AZN, AMGN, GENZ, GILD, CELG)

Novartis AG (NYSE: NVS) shares are at session highs and well of the lows of the day in the early afternoon Thursday after Japan okayed one of the company’s human growth hormones, the first approval in Japan of a generic biotech drug.  With the recent talks of President Obama wanting generic biologics, the approval process in Japan is probably not an isolated event and should not be ignored for broader implications.
Read More »

Posted on: June 25, 2009 – 11:31 am in Biotech, Drug companies, FDA, Medical, Politics, , , , , , ,

Media Digest 6/17/2009 Reuters, WSJ, NYTimes, FT, Bloomberg

newspaperReuters: The US faces a long period of economic stagnation.

Reuters:   Obama will release plans for a financial market overhaul.

Reuters:   The White House will not help California fix its deficit.

Reuters:   Large US company bankruptcies are accelerating.

Retuers:   News Corp’s (NWS) MySpace fired 30% of its staff. Read More »

Posted on: June 17, 2009 – 3:08 am in Press Digest, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Genzyme Corp. Receives European Approval for its Kidney Disease Drug Renvela (GENZ)

camMonopoly_wideweb__430x325,0Biotech Genzyme Corp. (Nasdaq: GENZ) reported on Friday that it has received European approval for Renvela, a newer version of its Renagel drug to help control phosphate levels in the blood of chronic kidney disease patients.
Read More »

Posted on: June 13, 2009 – 6:49 am in Biotech, Pharmaceuticals,

Top Analyst Upgrades (ARUN, CTV, DPS, ESRX, GENZ, ISRG, LRCX, MXIM, NUAN)

These are some of the top analyst upgrades and positive research calls we have seen this Tuesday morning from Wall Street:

Aruba Networks (ARUN) Raised to Neutral at JPMorgan.
CommScope (CTV) Raised to Overweight at JPMorgan.
Dr Pepper Snapple (DPS) Raised to Neutral at JPMorgan.
Express Scripts (ESRX) Raised to Buy at UBS.
Genzyme (GENZ) Started as Buy at Collins Stewart.
Intuitive Surgical (ISRG) Raised to Buy at Lazard.
Lam Research (LRCX) Raised to Outperform at Oppenheimer.
Maxim (MXIM) Raised to Buy at Canaccord.
Nuance Communications (NUAN) Started as Buy at Canaccord.

JON C. OGG

Posted on: April 14, 2009 – 7:30 am in Analyst Calls, , , , , , , , ,

Piper Jaffray Initiates Coverage on Genzyme (GENZ) with a Buy; Attractive Entry Point

Piper Jaffray & Co. initiates coverage on Genzyme (Nasdaq: GENZ) with a Buy rating and $86 price target, citing steady growth with highly achievable catalysts.

Piper analyst says, “We believe GENZ shares offer steady growth with highly achievable NT catalysts. NT visibility into earnings combined with sophisticated use of its balance sheet for clinical partnerships puts the company in a stronger position to offer reliable growth at a highly reasonable price (currently trading at 11x our 2009 EPS forecast). Moreover, following the closing of Roche’s acquisition of DNA, we expect GENZ to be well positioned to capture a redeployment of profits…

Read more…

Posted on: March 27, 2009 – 8:20 am in Uncategorized,

Top 10 Analyst Upgrades & Downgrades (AMGN, COP, DD, GENZ, GS, MON, MOS, BBY, PBR, VMW)

These are ten of the top impact research calls with upgrades and downgrades from Wall Street early this Friday morning:

Amgen (AMGN) Raised to Overweight at JPMorgan.
ConocoPhillips (COP) Raised to Buy at Goldman Sachs.
DuPont (DD) Started as Buy at UBS.
Genzyme (GENZ) Started as Buy at Piper Jaffray.
Goldman Sachs (GS) Started as Outperform at FBR.
Monsanto (MON) Started as Buy at UBS.
Mosaic (MOS) Started as Buy at UBS.
Best Buy (BBY) Removed from Goldman Sachs Conviction Buy List, but maintained as “Buy.”
Petrobras (PBR) Cut to Hold at Deutsche Bank.
VMware (VMW) Cut to Sell at Auriga.

JON C. OGG
March 27, 2009

Posted on: March 27, 2009 – 6:59 am in Analyst Calls, , , , , , , , , ,

Top 10 Analyst Upgrades & Downgrades (AMZN, BBY, KO, GENZ, HAL, IPI, RIG, AFL, PBR, VE)

These are some of the top pre-market early bird analyst upgrades and downgrades from Wall Street this Monday morning:

  • Amazon.com (AMZN) Raised to Buy at Piper Jaffray.
  • Best Buy (BBY) Raised to Outperform at William Blair.
  • Coca-Cola (KO) Raised to Outperform at Credit Suisse.
  • Genzyme (GENZ) Raised to Buy at Deutsche Bank.
  • Halliburton (HAL) Raised to Outperform at FBR.
  • Intrepid Potash (IPI) Raised to Outperform at Oppenheimer.
  • Transocean (RIG) Raised to Outperform at FBR.
  • AFLAC (AFL) Cut to Sell at UBS.
  • Petrobras (PBR) Cut to Neutral at JPMorgan.
  • Veolia Environment SA (VE) Cut to Underperform at Credit Suisse.

JON C. OGG

Posted on: March 9, 2009 – 6:42 am in Analyst Calls, , , , , , , , , ,

The 52-Week Low Club (GE)(AIG)(MET)(ACAS)(GENZ)

sad_clown1GE (GE) Growing concern that financial division will have heavy write-offs. Drops to $6.85 from a 52-week high of $38.52.

MetLife (MET) One of many insurance companies being pulled down by AIG (AIG). Falls to $13.41 from 52-week high of $65.50.

American Capital (ACAS) Credit rating cut. Sells off to $.85 from 52-week high of $37.30.

Genzyme (GENZ) FDA delays approval of one of the company’s drugs. Plunges to $50.05 from 52-week high of $83.97.

Douglas A. McIntyre

Posted on: March 3, 2009 – 3:59 pm in HI/LOW, , , , ,